The annual product quality review procedure was inadequate.
Inspection Record
Baxter Corporation — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The maintenance of evidence was inadequate for manufacturing, packaging, labelling, required testing, storage, and/or distribution, including the respective conditions. Documents were not available on the premises.
Investigations into deviations, reports, and/or follow-up actions were inadequate.
The evidence required to demonstrate compliance with finished product specifications was inadequate.
The ongoing stability program for a drug was inadequate.
The assessment, recording, follow-up, and/or investigation of complaints and/or other information about potentially defective products was inadequate.
The positive identification of each batch of drug after the packaging and/or after it was received on the importer's premises was inadequate.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Bonita Pharmaceuticals Inc.2026-08-13 · Health CanadaSimilar to finding 3 Investigations into deviations, reports, and/or follow-up actions were inadequate.
- Canadian Hospital Specialties Ltd2026-09-16 · Health CanadaSimilar to finding 1 The annual product quality review procedure was inadequate.
- Altamed Pharma2026-08-10 · Health CanadaSimilar to finding 1 The annual product quality review procedure was inadequate.
- Andone Pharmaceutical Inc2021-10-18 · Health CanadaSimilar to finding 5 The ongoing stability program for a drug was inadequate.
- Steri-Med Pharma Inc.2021-10-12 · Health CanadaSimilar to finding 5 The ongoing stability program for a drug was inadequate.
A record as of the Health Canada inspection on 2026-08-11. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.